The team is still exploring why that happens, but Spencer suspects that CDK4 and CDK6 may stand in the shadows throughout the cell cycle, ready to jump in and assist when CDK2 is impaired. She said ...

Citation: Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in some breast cancer (2022, September 16) retrieved 16 May 2025 from https ...

A new review was published in Genes & Cancer on August 25, 2022, entitled, “CDK4: a master regulator of the cell cycle and its role in cancer.” ...

Additional work focuses on the regulation of novel downstream substrates of the cyclin D1/CDK4 kinase and their role in mediating cyclin D1-dependent effects on tumor cell gene expression networks. A ...

In a paper published in Science China Life Sciences, researchers from Sun Yat-sen Memorial Hospital found that overexpressed Cyclin D1 and CDK4 proteins, caused by accelerated translation, led to ...

CDK4/6 Inhibitors in Breast Cancer: New Populations, Different Settings — Maryam Lustberg, MD, details three posters she was a discussant on at ASCO 2023.

DelveInsight's CDK4/6 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging CDK4/6 inhibitors, market share of individual therapies, and ...

Results showed the addition of CDK4/6 inhibitors in the first-line vs. second-line setting did not lead to a statistically significant nor clinically relevant PFS benefit (HR = 0.87; 95% CI, 0.74 ...

Early-phase trials hinted that camizestrant plus a CDK4/6 inhibitor could postpone tumor growth in people whose cancers already carried an ESR1 mutation. HR+, HER2- Advanced Breast Cancer.

A real-world analysis shows "meaningful" overall survival benefits when a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor is added to endocrine therapy for older women with HR-positive/HER2 ...

Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations. Please also include a discussion of capivasertib as a newly approved option based on the ...